GB201117428D0 - Structured polypeptides with sarcosine linkers - Google Patents

Structured polypeptides with sarcosine linkers

Info

Publication number
GB201117428D0
GB201117428D0 GBGB1117428.1A GB201117428A GB201117428D0 GB 201117428 D0 GB201117428 D0 GB 201117428D0 GB 201117428 A GB201117428 A GB 201117428A GB 201117428 D0 GB201117428 D0 GB 201117428D0
Authority
GB
United Kingdom
Prior art keywords
sarcosine
polypeptide
linkers
structured polypeptides
reactive groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1117428.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bicycle Therapeutics PLC
Original Assignee
Bicycle Therapeutics PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bicycle Therapeutics PLC filed Critical Bicycle Therapeutics PLC
Priority to GBGB1117428.1A priority Critical patent/GB201117428D0/en
Publication of GB201117428D0 publication Critical patent/GB201117428D0/en
Priority to PCT/EP2012/069899 priority patent/WO2013050617A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Abstract

The invention provides a polypeptide ligand comprising a polypeptide comprising at least three reactive groups, separated by at least two loop sequences, and a molecular scaffold which forms covalent bonds with the reactive groups of the polypeptide such that at least two polypeptide loops are formed on the molecular scaffold, further comprising an amino acid polymer comprising at least two sarcosine monomers.
GBGB1117428.1A 2011-10-07 2011-10-07 Structured polypeptides with sarcosine linkers Ceased GB201117428D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1117428.1A GB201117428D0 (en) 2011-10-07 2011-10-07 Structured polypeptides with sarcosine linkers
PCT/EP2012/069899 WO2013050617A1 (en) 2011-10-07 2012-10-08 Structured polypeptides with sarcosine linkers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1117428.1A GB201117428D0 (en) 2011-10-07 2011-10-07 Structured polypeptides with sarcosine linkers

Publications (1)

Publication Number Publication Date
GB201117428D0 true GB201117428D0 (en) 2011-11-23

Family

ID=45091776

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1117428.1A Ceased GB201117428D0 (en) 2011-10-07 2011-10-07 Structured polypeptides with sarcosine linkers

Country Status (2)

Country Link
GB (1) GB201117428D0 (en)
WO (1) WO2013050617A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2764140B1 (en) 2011-10-07 2017-08-30 Bicycle Therapeutics Limited Modulation of structured polypeptide specificity
GB201306623D0 (en) 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
EP3062823B1 (en) 2013-10-28 2018-12-12 BicycleRD Limited Novel polypeptides
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited Bicyclic peptide ligands with detectable moieties and uses thereof
EP3700577A1 (en) * 2017-10-23 2020-09-02 Mablink Bioscience Ligand-drug-conjugate comprising a single molecular weight polysarcosine
WO2019084060A1 (en) 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. Conjugates and methods of use thereof for selective delivery of immune-modulatory agents
TWI825046B (en) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Bicyclic peptide ligands specific for epha2
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
GB201808835D0 (en) * 2018-05-30 2018-07-11 Bicyclerd Ltd Ligands and methods of selecting binding targets for such
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
EP3849971A2 (en) 2018-09-12 2021-07-21 Silverback Therapeutics, Inc. Substituted benzazepine compounds, conjugates, and uses thereof
SG11202101980VA (en) 2018-09-12 2021-03-30 Silverback Therapeutics Inc Methods and composition for the treatment of disease with immune stimulatory conjugates
WO2020054126A1 (en) * 2018-09-14 2020-03-19 国立研究開発法人理化学研究所 Method for introducing substance into target cell
MX2022001719A (en) 2019-08-15 2022-03-11 Silverback Therapeutics Inc Formulations of benzazepine conjugates and uses thereof.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
DK1844337T3 (en) 2005-01-24 2013-09-30 Pepscan Systems Bv Binding compounds, immunogenic compounds and peptide mimetics
US8691761B2 (en) * 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
ATE555200T1 (en) 2008-02-05 2012-05-15 Medical Res Council METHODS AND COMPOSITIONS
EP2288715B1 (en) 2008-04-11 2014-09-24 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
GB0913775D0 (en) 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides

Also Published As

Publication number Publication date
WO2013050617A9 (en) 2013-07-04
WO2013050617A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
GB201117428D0 (en) Structured polypeptides with sarcosine linkers
AU2019201173B2 (en) Novel polypeptides
MX340498B (en) Heterodimerized polypeptide.
NZ713439A (en) Modulation of structured polypeptide specificity
MX2018013981A (en) Improved peptide pharmaceuticals for insulin resistance.
CY1120426T1 (en) ACE2 polypeptide
BR112017006826A2 (en) new antagonist a4ss7 peptide monomers and dimers
MX344219B (en) Improved peptide pharmaceuticals for insulin resistance.
EP3712165A3 (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
WO2014040591A3 (en) Non-covalent, self-organising hydrogel matrix for biotechnological applications
WO2011018227A3 (en) Peptide libraries
UA118167C2 (en) Peptides and their use
GB201008902D0 (en) Membrane enhanced polymer sythesis
EP3919507A3 (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
MX2018001511A (en) Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same.
IL228813A0 (en) Amino acid sequences directed against il-17a,il-17f and/or il17-a/f polypeptides comprising the same
WO2012031243A3 (en) dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
WO2013000922A9 (en) Ccr2 antagonist peptides
MX347829B (en) Multivalent antigen-binding fv molecule.
WO2012158964A3 (en) Improved peptide pharmaceuticals for osteoporosis
MX2015001045A (en) Polymers, polymer membranes and methods of producing the same.
WO2012075147A3 (en) Stable helical ionic polypeptides
WO2014100481A3 (en) Modified alpha hemolysin polypeptides and methods of use
WO2015105738A3 (en) Chromium (iii) catalyst systems with activator-supports
MX2016002937A (en) Oncology vaccine.

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)